• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

中美洲和加勒比地区头颈部鳞状细胞癌铂类药物不适应证:共识。

Platinum ineligibility in squamous cell carcinoma of the head and neck: consensus from Central America and the Caribbean.

机构信息

Roosevelt Hospital, Guatemala City, Guatemala.

Alexander Fleming Institute of Oncology, Buenos Aires, Argentina.

出版信息

Future Oncol. 2021 May;17(15):1963-1971. doi: 10.2217/fon-2020-0931. Epub 2021 Feb 9.

DOI:10.2217/fon-2020-0931
PMID:33559505
Abstract

The high incidence of head and neck cancer in Central America and the Caribbean, together with limitations in the healthcare system for patients with locally advanced squamous cell carcinoma of the head and neck (LA SCCHN) in this region necessitate a consensus of opinion based on a review of the literature on therapy with cisplatin plus radiation. Such an approach will ensure appropriate selection of patients who can benefit from therapy and reduce the incidence of related adverse events. Therefore, we recorded the opinion of experts in the region in order to identify needs and challenges in the treatment of LA SCCHN.

摘要

中美洲和加勒比地区头颈部癌症的高发率,加上该地区局部晚期头颈部鳞状细胞癌(LA SCCHN)患者的医疗保健系统存在局限性,需要根据顺铂联合放疗治疗的文献综述达成共识。这种方法将确保对能够从治疗中获益的患者进行适当选择,并减少相关不良事件的发生率。因此,我们记录了该地区专家的意见,以确定治疗 LA SCCHN 的需求和挑战。

相似文献

1
Platinum ineligibility in squamous cell carcinoma of the head and neck: consensus from Central America and the Caribbean.中美洲和加勒比地区头颈部鳞状细胞癌铂类药物不适应证:共识。
Future Oncol. 2021 May;17(15):1963-1971. doi: 10.2217/fon-2020-0931. Epub 2021 Feb 9.
2
Avelumab-cetuximab-radiotherapy versus standards of care in locally advanced squamous-cell carcinoma of the head and neck: The safety phase of a randomised phase III trial GORTEC 2017-01 (REACH).avelumab-西妥昔单抗-放疗与头颈部局部晚期鳞状细胞癌的标准治疗比较:GORTEC 2017-01(REACH)随机 III 期试验的安全性阶段。
Eur J Cancer. 2020 Dec;141:21-29. doi: 10.1016/j.ejca.2020.09.008. Epub 2020 Oct 24.
3
Incidence and risk factors for acute kidney injury in head and neck cancer patients treated with concurrent chemoradiation with high-dose cisplatin.同期放化疗联合高剂量顺铂治疗头颈部癌患者急性肾损伤的发生率及危险因素。
BMC Cancer. 2019 Nov 8;19(1):1066. doi: 10.1186/s12885-019-6233-9.
4
Clinical decision pathway and management of locally advanced head and neck squamous cell carcinoma: A multidisciplinary consensus in Asia-Pacific.局部晚期头颈部鳞状细胞癌的临床决策路径和管理:亚太地区多学科共识。
Oral Oncol. 2024 Jan;148:106657. doi: 10.1016/j.oraloncology.2023.106657. Epub 2023 Dec 15.
5
Weekly Low-Dose Versus Three-Weekly High-Dose Cisplatin for Concurrent Chemoradiation in Locoregionally Advanced Non-Nasopharyngeal Head and Neck Cancer: A Systematic Review and Meta-Analysis of Aggregate Data.局部晚期非鼻咽癌头颈部癌同期放化疗中每周低剂量与三周高剂量顺铂的比较:汇总数据分析的系统评价和荟萃分析。
Oncologist. 2017 Sep;22(9):1056-1066. doi: 10.1634/theoncologist.2017-0015. Epub 2017 May 22.
6
Phase I trial of dacomitinib, a pan-human epidermal growth factor receptor (HER) inhibitor, with concurrent radiotherapy and cisplatin in patients with locoregionally advanced squamous cell carcinoma of the head and neck (XDC-001).达可替尼(一种泛人类表皮生长因子受体(HER)抑制剂)与同步放疗和顺铂联合用于局部区域晚期头颈部鳞状细胞癌患者的I期试验(XDC - 001)。
Invest New Drugs. 2016 Oct;34(5):575-83. doi: 10.1007/s10637-016-0367-2. Epub 2016 Jun 11.
7
A multicenter phase II trial of paclitaxel, carboplatin, and cetuximab followed by chemoradiotherapy in patients with unresectable locally advanced squamous cell carcinoma of the head and neck.紫杉醇、卡铂和西妥昔单抗联合放化疗治疗不可切除局部晚期头颈部鳞状细胞癌的多中心 II 期临床试验。
Cancer Med. 2020 Mar;9(5):1671-1682. doi: 10.1002/cam4.2852. Epub 2020 Jan 13.
8
Clinical recommendations for defining platinum unsuitable head and neck cancer patient populations on chemoradiotherapy: A literature review.关于在放化疗中定义铂类不适用头颈癌患者群体的临床建议:一项文献综述
Oral Oncol. 2016 Feb;53:10-6. doi: 10.1016/j.oraloncology.2015.11.019. Epub 2015 Dec 19.
9
A Phase II Study of Genexol-PM and Cisplatin as Induction Chemotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma.Genexol-PM 联合顺铂用于局部晚期头颈部鳞状细胞癌诱导化疗的 II 期研究。
Oncologist. 2019 Jun;24(6):751-e231. doi: 10.1634/theoncologist.2019-0070. Epub 2019 Feb 22.
10
Concurrent chemoradiotherapy with weekly versus triweekly cisplatin in locally advanced squamous cell carcinoma of the head and neck: Comparative analysis.同期放化疗联合每周与每三周顺铂治疗局部晚期头颈部鳞状细胞癌:比较分析。
Head Neck. 2019 May;41(5):1490-1498. doi: 10.1002/hed.25379. Epub 2019 Mar 5.